Many Catalent, Inc.(CTLT) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Catalent Inc was Initiated by Goldman to Neutral on Dec 1, 2016.
Company has reported several Insider transactions to the SEC, on Jun 1, 2016, Matthew M Walsh (officer ) sold 21,197 shares at 28.85 per share price.On Aug 19, 2015, John R Chiminski (director officer ) sold 38,505 shares at 33.87 per share price.On Apr 3, 2015, Scott Houlton (officer ) sold 16,253 shares at 30.61 per share price.
Catalent Inc Last issued its quarterly earnings results on Feb 6, 2017. The company reported $0.27 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $0.26. The company had revenue of $483.70 million for the quarter, compared to analysts expectations of $471.96 million. The companys revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.36 EPS.
Catalent, Inc. (NYSE:CTLT) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.91 by 11 Brokerage Firm. 6 Wall Street Firms have rated the stock as a strong buys. 5 Brokerage Firms have advised hold.
Catalent, Inc. (NYSE:CTLT): The mean estimate for the short term price target for Catalent, Inc. (NYSE:CTLT) stands at $30 according to 7 Analysts. The higher price target estimate for the stock has been calculated at $32 while the lower price target estimate is at $25.
Catalent, Inc. (NYSE:CTLT) rose 2.6% or 0.74 points on Tuesday and made its way into the gainers of the day. After trading began at $28.28 the stock was seen hitting $29.25 as a peak level and $28.19 as the lowest level. The stock ended up at $29.24. The daily volume was measured at 699,747 shares. The 52-week high of the share price is $32.24 and the 52-week low is $20.94. The company has a market cap of $3,648 million.
Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey.